SUN Pharma Adv.res.co.ltd
NSE: SPARC · Pharmaceuticals · sector
₹178.40NSE close 2026-10-26
Key numbers
Market cap₹5,789 cr
Price₹178.40
52w high / low₹289 / ₹108
P/E3.7xSector median 27.9x
P/B4.3xSector median 2.9x
Book value₹41.3
Dividend yield–Sector median 0.48%
ROE282.7%Sector median 11.7%
ROCE85.5%Sector median 12.3%
OPM84.0%Sector median 14.0%
Debt / equity0.42xSector median 0.16x
EV/EBITDA4.0xSector median 18.6x
Interest cover44.9x
Current ratio2.47x
Sales growth 3y+98.9%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1 cr vs borrowings ₹556 cr (FY26): borrowings are higher by ₹555 cr.
- Borrowings rose in each of the last 3 years (₹0 cr → ₹556 cr).
- Operating profit covered interest 44.9x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY25, FY24, FY22).
- Net loss in 7 of the last 8 quarters.
- Revenue was higher than a year earlier in 2 of the last 4 quarters.
- Other income was 2% of net profit in the last 12 months.
- Debtor days went from 75 (FY24) to 2 (FY26).
- No dividend in the last 5 financial years.
- Price ₹178.40 on 2026-10-26: -38.3% from the 52-week high, +65.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹269.98 · low ₹108.71
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 |
| EBITDA | -103 | -74 | -53 | -52 | -66 | -69 | 1,773 | -34 |
| OPM % | -800.2% | -494.2% | -195.6% | -540.2% | -836.1% | -816.6% | 95.7% | -85.2% |
| Other income | 0 | 0 | 0 | 9 | 0 | 0 | 2 | 24 |
| Net profit | -107 | -80 | -60 | -52 | -76 | -80 | 1,763 | -21 |
| EPS (₹) | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 | -0.64 |
| Revenue YoY | -38.9% | -43.3% | +6,715.8% | +314.1% | ||||
| Profit YoY | – | – | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 137 | 239 | 76 | 72 | 1,879 | 1,909 |
| EBITDA | -187 | -214 | -402 | -323 | 1,586 | 1,604 |
| Net profit | -203 | -223 | -387 | -343 | 1,556 | 1,586 |
| EPS (₹) | -7.73 | -7.82 | -11.93 | -10.55 | 47.86 | 48.81 |
| Revenue growth | +74.0% | -68.4% | -5.0% | +2,518.3% | +2,855.8% | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +98.9% | +49.3% | +2,855.8% |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -7.4% (2y) | +36.0% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 513 | 126 | -217 | 1,339 |
| Borrowings | – | 0 | 47 | 258 | 556 |
| Cash & equivalents | – | 402 | 157 | 2 | 1 |
| Total assets | – | 830 | 515 | 336 | 2,171 |
| Fixed assets | – | 105 | 107 | 99 | 85 |
| Capital work in progress | – | 2 | 1 | 1 | 0 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 33 | 16 | 16 | 8 |
| Inventory | – | 0 | 0 | 0 | 0 |
| Payables | – | 148 | 142 | 114 | 97 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -208 | -69 | -429 | -360 | -239 |
| Cash from investing | -29 | -548 | 392 | 158 | -24 |
| Cash from financing | 229 | 617 | 42 | 199 | 261 |
| Capex | 33 | 15 | 27 | 10 | 24 |
| Free cash flow | -241 | -85 | -456 | -371 | -263 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -43.4% | -307.9% | 158.0% | 116.2% |
| ROCE % | – | -41.9% | -222.9% | -809.3% | 83.8% |
| Debtor days | – | 50 | 75 | 82 | 2 |
| Inventory days | – | 0 | 0 | 0 | 0 |
| Payable days | – | 2,448 | 1,846 | 1,798 | 1,503 |
| Cash conversion cycle (days) | – | -2,398 | -1,771 | -1,716 | -1,501 |
| Working capital days | – | 422 | 21 | -1,770 | 215 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 65.67% |
| FIIs | 3.75% |
| DIIs | 0.11% |
| of which Mutual funds | 0.10% |
| Government | 0.00% |
| Public (non-institutions) | 30.48% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | May 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% |
| Promoter group | % |
|---|---|
| Shanghvi Finance Private Limited | 42.28% |
| Dilip.S.Shanghvi | 19.05% |
| Sun Pharmaceutical Industries Key Employees Benefit Trust | 3.18% |
| Aditya Medisales Limited | 1.51% |
| Raksha Sudhir Valia | 1.28% |
| Sudhir Vrundavandas Valia | 0.57% |
| Unimed Investments Limited | 0.39% |
| Vibha Dilip Shanghvi | 0.33% |
| Aalok Dilip Shanghvi | 0.11% |
| Vidhi Dilip Shanghvi | 0.11% |
| Shanghvi Family & Friends Benefit Trust | 0.05% |
| Kumud Shantilal Shanghvi | 0.01% |
| Krishna Vrundavandas Valia | 0.00% |
| Flamboyawer Finance Private Limited | 0.00% |
| Shanghvi Universal Private Limited | 0.00% |
| Public holders above 1% | % |
|---|---|
| Lakshdeep Investments & Finance (P) Ltd. | 1.86% |
| Paresh Mohanlal Parekh | 1.13% |
| Vijay Mohanlal Parekh | 1.13% |
| Enam Holdings Pvt Ltd | 1.04% |
1,41,992 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SPARC | ₹5,789 cr | 3.7x | 4.3x | 282.7% | 85.5% | 84.0% | +98.9% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2021-09-21 | Other | Annual General Meeting |
| 2020-09-22 | Other | Annual General Meeting |
| 2019-07-18 | Other | Annual General Meeting |
| 2018-07-19 | Other | Annual General Meeting |
| 2017-07-27 | Other | Annual General Meeting |
| 2017-05-25 | Other | Extraordinary General Meeting |
| 2016-07-21 | Other | Annual General Meeting |
| 2016-03-16 | Rights | Rights 5: 116 At Premium Rs 244/- Per Share |
| 2015-07-23 | Other | Annual General Meeting |
| 2014-07-24 | Other | Annual General Meeting |
| 2013-07-24 | Other | Annual General Meeting |
| 2012-08-23 | Rights | Rights 1: 7@ Premium Rs 66 Per Share |
| 2011-07-28 | Other | Annual General Meeting |
| 2010-07-16 | Other | Annual General Meeting |
| 2009-08-21 | Other | Annual General Meeting |
| 2008-08-25 | Other | Annual General Meeting |
| 2007-08-28 | Other | Agm |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Professional, Scientific and Technical: Scientific Research and Development
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SPARC |
| BSE code | 532872 |
| ISIN | INE232I01014 |
| Face value | ₹1.0 |
| Incorporated | 2006-03-01 |
| Website | https://sparc.life |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.